抗苗勒管激素用于判定多囊卵巢形态
本研究为回顾性多中心病例对照的APHRODITE研究,采用Elecsys AMH Plus免疫分析法测定血清抗苗勒管激素(AMH),以经阴道超声窦卵泡计数判定多囊卵巢形态(PCOM)。在验证队列(455例病例和500例对照)中得出AMH切点3.2 ng/mL(23 pmol/L),诊断PCOM的敏感性88.6%、特异性84.6%,AUC 93.6%。
要点
- Elecsys AMH Plus免疫分析法诊断PCOM的切点为3.2 ng/mL(23 pmol/L)。
- 验证队列中该切点敏感性88.6%、特异性84.6%,AUC 93.6%。
- 25-35岁女性敏感性88.5%、特异性80.3%,36-45岁分别为77.8%和90.1%。
核心结论
- Elecsys AMH Plus免疫分析法以3.2 ng/mL(23 pmol/L)为切点,是识别PCOM以辅助诊断PCOS的稳健方法。
研究设计与样本
- APHRODITE研究为回顾性、多中心、病例对照研究,采用Elecsys AMH Plus免疫分析法测血清AMH,经阴道超声测窦卵泡计数。
- 在独立队列中推导并验证AMH切点,病例为具有完整表型A(稀发/无排卵、高雄激素血症和PCOM)的PCOS患者,对照为PCOS阴性女性。
- 研究对象为25-45岁PCOS阳性(按Rotterdam标准A-D型)和PCOS阴性女性。
主要发现
- 验证队列(455例病例和500例对照)中,AMH切点3.2 ng/mL(23 pmol/L)诊断PCOM的敏感性为88.6%(95%CI 85.3-91.3),特异性为84.6%(95%CI 81.1-87.7)。
- 该切点的受试者工作特征曲线下面积为93.6%(95%CI 92.2-95.1)。
- 25-35岁女性中该切点的敏感性和特异性分别为88.5%和80.3%,36-45岁女性分别为77.8%和90.1%。
- 结果在PCOS表型A-D中一致。
关键数值与推荐
- AMH切点3.2 ng/mL(23 pmol/L)用于Elecsys AMH Plus免疫分析法识别PCOM。
- 验证队列中该切点诊断PCOM的敏感性88.6%(95%CI 85.3-91.3),特异性84.6%(95%CI 81.1-87.7),AUC 93.6%(95%CI 92.2-95.1)。
- 25-35岁女性敏感性88.5%、特异性80.3%;36-45岁女性敏感性77.8%、特异性90.1%。
临床怎么用
- 临床可采用Elecsys AMH Plus免疫分析法测AMH,以3.2 ng/mL(23 pmol/L)为切点辅助识别PCOM,助力PCOS诊断。
- 解读切点时应考虑年龄:25-35岁女性敏感性较高而特异性较低,36-45岁女性特异性较高而敏感性较低。
局限性
- 本研究为回顾性病例对照设计。
- 探索性分析按年龄和PCOS表型进行,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine a cutoff for the Elecsys AMH Plus immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) to identify polycystic ovarian morphology (PCOM), a polycystic ovary syndrome (PCOS) criterion. DESIGN: The AMH Protein in Humans for polycystic ovaRian mOrphology DIagnostic TEsting (APHRODITE) study was a retrospective, multicenter, case-control study. The serum antimüllerian hormone (AMH) level was measured using the Elecsys AMH Plus immunoassay. The antral follicle count was determined using transvaginal ultrasound. An AMH cutoff was derived and validated in separate cohorts with cases of PCOS with full phenotype A (oligo/anovulation, hyperandrogenism, and PCOM) versus that with controls. Exploratory analyses of age and PCOS phenotype were performed. SETTING: Not applicable. PATIENT(S): Polycystic ovary syndrome-positive (PCOS A-D per the Rotterdam criteria) and PCOS-negative women aged 25-45 years. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): A validated cutoff for AMH using the Elecsys AMH Plus assay for PCOM. RESULT(S): In the validation cohort (455 cases and 500 controls), an AMH cutoff of 3.2 ng/mL (23 pmol/L) resulted in a sensitivity of 88.6% (95% confidence interval [CI] 85.3-91.3) and specificity of 84.6% (95% CI 81.1-87.7) for PCOM diagnosis as well as an area under the receiver-operator characteristic curve of 93.6% (95% CI 92.2-95.1). In women aged 25-35 years, the sensitivity and specificity for the cutoff were 88.5% and 80.3%, respectively, versus 77.8% and 90.1%, respectively, in women aged 36-45 years. The results were consistent across PCOS phenotypes A-D. CONCLUSION(S): The Elecsys AMH Plus immunoassay, with a cutoff of 3.2 ng/mL (23 pmol/L), is a robust method for identifying PCOM to aid in PCOS diagnosis.
引用
- Dietz de Loos A, Hund M, Buck K, et al. Antimüllerian hormone to determine polycystic ovarian morphology. Fertil Steril. 2021. PMID: 34579824. doi:10.1016/j.fertnstert.2021.05.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。